Scientist Home Future Health Limited

What they do

The company operates through its wholly owned Hong Kong subsidiary, Scientist Home HK, which sells health supplements and topical creams at retail and provides physical check-up services. It was incorporated in Nevada on July 3, 2024 and acquired Scientist Home Holding, a Marshall Islands vehicle, on September 26, 2024 for $1.00 from CEO and director Chan Siu Hung, a related party transaction. Operations are focused on Hong Kong, with stated plans to expand into neighboring Asian markets. The 10-K states there is no scientific evidence supporting health claims for its products, which are described as the company's opinions or beliefs.

Revenue drivers

• Retail sale of health supplements and topical creams — Generated $197,447 of fiscal 2025 revenue, the large majority of the $204,055 total, with cost of retail trading revenue of $121,075; product costs are set at 50% off recommended retail price under a non-exclusive distributor agreement with Scientist Home Limited.
• Physical check-up services — Contributed $6,608 of fiscal 2025 revenue with cost of service revenue of $1,093, mainly medical supplies; a small service line relative to product retail.
• Product portfolio — The 10-K describes six initial primary products, health supplements and topical creams for specific health concerns; the excerpt names only Scientist Home Vein Cream, an external body cream formulated for hemorrhoid and varicose discomfort.

Recent performance

Fiscal 2025 revenue was $204,055, split between $197,447 of retail product sales and $6,608 of check-up services, up from $120,775 in the period ended December 31, 2024. Cost of revenues rose to $122,168 from $67,865, and general and administrative expenses jumped to $313,612 from $66,065, producing a net loss of $231,725 versus $14,980. Operating cash use was $248,278 for fiscal 2025, and cash rose to $68,888 at December 31, 2025 from $18,621, attributed to stock sale proceeds. Quarterly revenue in the latest filings was $39,604 (2025-09-30), $81,467 (2025-12-31), $182,278 (2026-03-31) and $82,878 (2026-06-30). At June 30, 2026, total assets were $529,844, total liabilities $616,168, shareholder equity was negative $86,324, and cash was $9,047.

Strategy

The company describes a mission to develop sustainable rehabilitation solutions, particularly for degenerative diseases, and positions itself as expanding from Hong Kong into neighboring Asian markets. In fiscal 2025 it raised $354,000 by issuing 236,000 shares at $1.5 per share and funded operations largely through equity sales. It holds two Hong Kong office leases, including one at Wing On Plaza running to September 15, 2028 with a renewal option through 2031 at a 4% annual rent increase. Management states that continuation depends on improving profitability and continued financial support from major shareholders or external financing. The 10-Q forward-looking section also references efforts to consummate a merger and the continued services of a custodian, though the excerpt does not describe those arrangements.

Risks

• Going concern doubt — The company incurred a $231,725 net loss and $248,278 of operating cash use in fiscal 2025, and its auditor expressed substantial doubt about its ability to continue as a going concern.
• Negative shareholder equity and thin cash — At June 30, 2026, shareholder equity was negative $86,324, total liabilities of $616,168 exceeded total assets of $529,844, and cash stood at just $9,047.
• Thin, thinly traded microcap with key-person and related-party concentration — The company was formed in July 2024, its CEO Chan Siu Hung holds all senior officer and director roles, and it acquired its holding company from him for $1.00 in a related party transaction.
• No scientific substantiation for product claims — The 10-K states there is no scientific evidence that the products address the health concerns described, which are presented only as the company's opinions or beliefs.

Outlook

Management says the company's ability to continue as a going concern depends on improving profitability and continued financial support from major shareholders or external financing, and it warns that no assurance can be given that future financing will be available or on satisfactory terms. Stated plans include expanding the Hong Kong operations into neighboring Asian markets and, per the 10-Q forward-looking language, consummating a merger and continuing a custodian's services. The filings note that additional debt could carry restrictive terms and additional equity could cause substantial shareholder dilution.